Detection of galactomannan content in generic piperacillin-tazobactam products-Reference-Cited by-同舟云学术

Detection of galactomannan content in generic piperacillin-tazobactam products

Published:2018-10-29 Issue:2 Volume:51 Page:157-159
ISSN:2374-4235
Container-title:Infectious Diseases
language:en
Short-container-title:Infectious Diseases

Author:

Saez de la Fuente Javier¹^ORCID,Campelo-Gutierrez Carolina²,Izquierdo-Garcia Elsa¹,Aznar Esteban²,Caro Jose Manuel³,Gimenez-Manzorro Alvaro⁴,Diaz Benito Garcia⁵,Becares Javier⁶

Affiliation:

1. Pharmacy Department, Hospital Universitario Infanta Leonor, Madrid, Spain;

2. BR. Salud. Microbiology Department, Hospital Universitario Infanta Leonor, Madrid, Spain;

3. Pharmacy Department, Hospital Universitario 12 de Octubre, Madrid, Spain;

4. Pharmacy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain;

5. Pharmacy Department, Hospital Universitario Severo Ochoa, Leganés Madrid, Spain;

6. Pharmacy Department, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23744235.2018.1530451

Reference10 articles.

1. The unexpected benefits of the national piperacillin/tazobactam shortage on antibiotic stewardship

2. False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem?

3. False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam—is it still an issue?

4. Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible for false-positive results of the galactomannan assay

5. Reduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States